Claims for Patent: 5,010,070

Summary for Patent: 5,010,070

Title:	Graduated estrogen contraceptive
Abstract:	Contraceptive methods and delivery systems involving few undesirable side effects during administration are based on novel triphasic estrogen/progestogen combinations, wherein the amount of estrogen is increased stepwise over the three phases.
Inventor(s):	Boissonneault; Roger M. (Long Valley, NJ)
Assignee:	Warner-Lambert Company (Morris Plains, NJ)
Application Number:	07/526,934
Patent Claims:	1. A multiphase combination and contraceptive kit comprising a package containing daily dosages of: (1) a Phase I composition containing about 0.5-1.5 mg norethindrone acetate and about 10-50 mcg ethinyl estradiol; ( 2) a Phase II composition containing about 0.5-1.5 mg norethindrone acetate and about 10-50 mcg ethinyl estradiol; and (3) a Phase III composition containing about 0.5-1.5 mg norethindrone acetate and about 10-50 mcg ethinyl estradiol, wherein the amount of ethinyl estradiol is increased stepwise over the three compositions. 2. The kit of claim 1 which additionally comprises a Phase IV composition containing ferrous fumarate. 3. The kit of claim 2 wherein the composition for Phase IV contains about 75 mg ferrous fumarate. 4. A multiphase combination and contraceptive kit comprising a package containing: (1) about 4 to 7 dosages of a Phase I composition containing about 0.5-1.5 mg norethindrone acetate and about 10-30 mcg ethinyl estradiol; (2) about 5 to 8 dosages of a Phase II composition containing about 0.5-1.5 mg norethindrone acetate and about 20-40 mcg ethinyl estradiol, and (3) about 7 to 12 dosages of a Phase III composition containing about 0.5-1.5 mg norethindrone acetate and about 30-50 mcg ethinyl estradiol, wherein the amount of ethinyl estradiol is increased stepwise over the three compositions. 5. The kit of claim 4 which additionally comprises about 9 dosages of a Phase IV composition containing ferrous fumarate. 6. The kit of claim 5 wherein the composition for Phase IV contains about 75 mg ferrous fumarate. 7. The kit of claim 4 wherein the Phase I composition contains about 1.0 mg norethindrone acetate and about 20 mcg ethinyl estradiol; the Phase II composition contains about 1.0 mg norethindrone acetate and about 30 mcg ethinyl estradiol; and the Phase III composition contains about 1.0 mg norethindrone acetate and about 40 mcg ethinyl estradiol. 8. The kit of claim 7 containing about 5 dosages of the Phase I composition, about 7 dosages of the Phase II composition, and about 9 dosages of the Phase III composition. 9. The kit of claim 4 wherein the Phase I composition contains about 1.0 mg norethindrone acetate and about 20 mcg ethinyl estradiol; Phase II composition contains about 1.5 mg norethindrone acetate and about 30 mcg ethinyl estradiol; and the Phase III composition contains about 1.0 mg norethindrone acetate and about 50 mcg ethinyl estradiol. 10. The kit of claim 9 containing about 5 dosages of the Phase I composition, about 7 dosages of the Phase II composition, and about 9 dosages of the Phase III composition. 11. The kit of claim 4 wherein the Phase I composition contains about 1.0 mg norethindrone acetate and about 20 mcg ethinyl estradiol; the Phase II composition contains about 1.0 mg norethindrone acetate and about 30 mcg ethinyl estradiol; and the Phase III composition contains about 1.0 mg norethindrone acetate and about 35 mcg ethinyl estradiol. 12. The kit of claim 11 containing about 5 dosages of the Phase I composition, about 7 dosages of the Phase II composition, and about 9 dosages of the Phase III composition.